our priorities we you which a longer X than a on call people realize and Slide today's cancer Melissa corporate future before. provides and us as live thank of summary with and Thank everyone to ever to in joining for you, better strive high-level webcast. current
updates We for program. two recently significant our announced lead
to EXXXX filing, near-term closer This breast to launch will us approval, at First, in Data passed hormone communicated a final last interim metastatic Board potential and receptor FDA its to events. brings Safety and has us proceed analysis its positive that the analysis has ECOG Monitoring XXX and cancer.
we patients of our highly have AUGMENT-XXX second event The begun that our Phase I inhibitor in is dosing designed SNDX-XXXX. selective Menin rationally important trial
result evolution a of exciting accomplishment, are Syndax. the of chapter and now entering in As a this we new
us broadens takes leukemias portfolio. have genetically the Both program of to defined new SNDX-XXXX acute the and into medicines. treatment our The potential become important importantly, programs
prospects We expect entinostat and future to six over the XX much the SNDX-XXXX of know months. about more to next both
some cancer. receptor the to now trial final greater So, design focus plus trial in The X And breast overall of the placebo clearly on III detail. summarizes versus let's randomized positive Phase HERX-negative XXX trial review entinostat. hormone exemestane is analysis. survival of in this entinostat these the plus patients opportunities Slide the of exemestane
modeling, Based our we occur analysis in XXX once that will based of there final full the are conducted final events. of upon quarter readout The believe year. events EXXXX sometime will next second the the on be XXX
our and Positive designation cancer terms outcome regulatory protocol U.S. receptor breakthrough file FDA. approval therapy the the with to based upon assessment the hormone positive special metastatic for allow of in in would us our breast
a ECOG, from entinostat regulatory the receiving up XXXX. to which trial would is us months six prepared launch filing submit about Our of the team within positive data to set be should in
ratio and ratio to study. design trial, the of of poised everyone to As trial I'd a trial in the significant positive yield the hazard for hazard maximum of the detect that readout moment The would the XX% X.XX a has X.XX. assumptions passed used were remind utility like EXXXX and power statistically we now successfully a are to have of analyses take five that final the of
median combination had overall design of combination survival that patients to improvement in X.XX; ratio the would control XX overall the XX in receiving a arm. hazard indicate overall arm months a that median about assumptions, survival about if survival upon from the months the median Based five-month EXXXX in reached about
research physicians to meaningful. be confident for important market remain clinically of We positive Our indicates a be that prescribing potential perceived survival by this in the and overall benefit EXXXX magnitude in to trial. is
Slide emphasizes for or a single be entinostat-exemestane given the regimen after agent X to CDKX/X potential combination a typically either inhibitor, which as with the first-line aromatase inhibitor. the agent preferred is in
a Our CDKX/X a our post CDKX/X Thus have half highly of a to in entering patient will have third current between and the is trial. we inhibitor in data that population. estimate should patients XXXX the prior relevant set received
the as of desire rapid to the first-line therapy. associated opinion, antiestrogen improve with patients such setting our CDKX/X adoption outcomes Ibrance physicians and the in inhibitors of In underscores the
could of the entinostat entinostat setting patients to similar therefore a substantial would receive go and regimen. expect widespread with patients population EXXXX XX,XXX therapy who the on result, This receive use. we eligible after failing achieve estimated to each first-line therapy who to be positive of is In year hormone an
Importantly, entinostat potential to commercial we our XXXX. in launch in on entinostat are launch own team positioned U.S. of well building we prepared our and be we out actively the will to ensure internal are for the
overview dose now to we I'll review shortly, SNDX-XXXX. news in trial but the like to first that turn agent. genetically I'd the me the brief patient a SNDX-XXXX Let Yesterday, of our that AUGMENT-XXX provide announced targeted exciting first tested trial.
the development Slide from fusion a of derived a that derived This half X is variety protein MLL-r. SNDX-XXXX. from the by of driven Mixed Lineage Leukemias known and partners. MLLX protein half underlies fusion protein biology as summarizes fusion are
creature a half the while the protein binds half-horse. the The fusion fusion of in involved For transcription, MLL activating is as a cancer-producing half for program. Centaur, think to scaffolding and protein responsible the Menin, a fans Greek of can mythology, half-human you transcription other recruiting mythological that is of protein
block potent orally rationally defined small interaction. Menin This molecular the specific has the to this level. molecule. been between is MLLX as Slide has designed fusion the a of on protein SNDX-XXXX interaction available illustrated and X, And SNDX-XXXX half at been and
illustration portion protein fusion is causes protein of how results a cancer. SNDX-XXXX bound Slide see that genes protein and left to DNA. how cancer complex of cause Menin work. the half an should of the fusion family This In activation in of the the the fusion attracting multi-protein of X partner panel, we a and to MLLX
In dies. The on turned the the differentiates that and you activated the Menin and to are displacing right, that panel can accompanying protein see complex. fusion were cell off the cancer and SNDX-XXXX multi-protein binds its genes
We've showing mechanism anticancer presented preclinical potent mutant NPMX and in-vivo MLL-r and in data leukemias numerous that has this both effects models leukemias. of sustained extensive
understanding we program. AUGMENT X inhibition accelerated call summarized On or first-in-human of the we Menin in Slide trial what the
and recommended trial I/Phase I trial. Phase trial Phase designed dose clinical combined of the a tolerated The a escalation a first-in-human The dose is maximum identify Phase II portion dose SNDX-XXXX. II is to
toxicity. Patients progressive relapsed acute they unacceptable disease leukemia or by until or will mouth SNDX-XXXX daily experienced with be either refractory and enrolled will take
The first not XX of Phase specific the to in genetic serve determining abnormalities in period have I is enroll days escalation. to safety as Patients order dosing the in are of which for required study. will dose evaluated portion the
of Upon X+X -- with dose upon an required encountering pre-specified toxicity, will first standard level only the cohort. design. a per The patient follow to a label trial convert entering one titration pre-specified accelerated a cohorts
We efficacy. assess safety pharmacokinetics, and will carefully
single X explored the It of number dependent encountered. XX be this cohort. enrollment announced on first the toxicities is in the has trial patient first that of Phase cohorts patient upwards with the anticipated the need commenced week portion that in with in We number patients to and precise that that maybe enrolled are our the AUGMENT-XXX
I want to is emphasize key the that the trial. of component X PK analysis a Phase
interaction the achieve be inhibited that optimal Our order in Menin-MLL-r preclinical continuously needs indicates data to efficacy. to
so, we indeed adequate we in coverage. exposures drug target will to the assess And examining be whether achieving carefully are patients
the forward mutant PK as these population. MLL-r likelihood will of first dose single-agent data timing seeing significantly look efficacy inform to initial rearranged and NPMX We the and those leukemic data the in cohorts in
efficacy efficacy patients X are data with that exploratory to not believe PK the than to assessments the an in trial, order have more Given Phase enroll we Phase portion the that specific from informative genetic being the be abnormalities could of portion X in objective. required
bode the X X we specific the will trial believe consists target refractory achieving enroll of that trial distinct the Phase relapse coverage the to in safely dose for is a X established, Once genetically efficacy Phase proceed Phase expansion cohorts, or of could well I three Phase Furthermore, which portion. recommended adequate defined in leukemia. establishing each acute
CML. with will rate The provide acute The Phase of are AML; mutant measure complete portion lymphoid three adults SNDX-XXXX MLL-r of the acute leukemia myeloid leukemia benefit. will and MLL-r X the cohorts as of initial NPMX and primary with an estimate response safety the with characterize further therapeutic adults adults ALL;
data initial first from a to physicians that and trial. patients, know eager lot We are see investors people, AUGMENT of the
data. running, to Given as when we up provide specific the that will getting possible trial just and present not guidance are to it's we
to we data As should progresses. clinical expect trial as of We report sense in data the trial to of better you be give now, the a able XXXX. from initial timing the
of advance key the eager timing strategy. of this is the into pediatric It our we pediatric details In component to molecule to about are more the will say addition, And we a overall future pediatric patients. we're bring population. significant a to a medical their MLL-r oncology and to the unmet to We leukemias approach work community call. and pediatric represent with rearrangements know on need, eager SNDX-XXXX with have
of evidence underlying activity. the pathway, the single-agent Based upon biology preclinical and are expecting data we of
As or agents there path be for clinical could development perhaps for taken path patients result, similar with a addressing IDH mutations. straightforward and to rapid a the XXXX, FLTX
continue becoming in and driver additional to molecule potential the see important for we an leukaemia, learn SNDX-XXXX of As we Syndax. more this about acute value
monoclonal Let and best-in-class me SNDX-XXXX, the XX to targeting turn potential CSF-X therapy now receptor. our slide antibody
graft-versus-host donor-derived chronic of as of are development hematopoietic wherein the and frequent cells of stem a graft-versus-host trial a advanced many initiation disease disease immune testing monotherapy the cell disease. and is transplantation We the conducting Chronic of symptoms. fibrosis complication contribute XXXX to in manifestation
antibody, believe opportunity. preclinical important chronic CSF-XR that chronic can of it models, donor blockade in reducing the an and We graft-versus-host of disease. preventing CSF-X, thereby depletion axis disease the result an graft-versus-host macrophages with In clinical represents
call the I ibrutinib IND required FDA the disease that to whose therapy. mentioned after on steroids and both study, when patients our that was for had we cleared enrollment our limit last progressed
the now is to enrollment hope bit the half criteria, population, set FDA are to ibrutinib an been to slower of now on used currently broader modify treat program frequently this update enroll to not a second as enrollment in we year. We've provide patients. with has However, next this than position the a and anticipated. in worked We a of
acquisition inflection Finally, slide acquisition the through the to that MLL-r We XX and to continue the valuable points believe of be development led expect such will our among clinical believe that SNDX-XXXX in-licensing assets. Menin of pipeline that transactions expertise quality program. to necessary differentiated remain to and the able of we partners through or transactions. the expand have these summarizes bring preferred We program we to compounds
over turn review to will I results. will now financial our call who the Rick,
